CD27L/CD70 Extracellular Domain (human, recombinant)

CD27L|TNF Superfamily Member 7|TNFSF7

CD70, also known as CD27 ligand (CD27L), is a type II transmembrane glycoprotein and member of the tumor necrosis factor (TNF) ligand superfamily (TNFSF).{59406} It is comprised of an N-terminal extracellular domain, a transmembrane domain, a stalk region, and a C-terminal TNF homology domain and is exclusively expressed on activated T and B cells and mature dendritic cells.{59406,13302,52860} CD70 forms homotrimers and binds to its receptor, CD27 (Item No. 31828), on antigen-primed T cells, which induces NF-κB and MAPK signaling through TNF receptor-associated factors (TRAFs) and, when the T cell is stimulated by other factors, induces PI3K signaling to induce the co-stimulation and expansion of naïve CD4+ and CD8+ T cells.{54194,59406} CD70 is overexpressed in various hematological malignancies and is associated with accelerated tumor cell proliferation.{52860} CD70 expression is negatively correlated with overall survival in patients with diffuse malignant mesothelioma of the pleura. Cayman’s CD27L/CD70 Extracellular Domain (human, recombinant) protein can be used for binding assay applications. This protein is a disulfide-linked homodimer. The reduced monomer, comprised of CD70 (amino acids 39-193) fused to human IgG Fc at its N-terminus, consists of 413 amino acids and has a calculated molecular weight of 45.5 kDa. As a result of glycosylation, the monomer migrates at approximately 55-60, 110-120, and 160-170 kDa, corresponding to the monomeric, dimeric and trimeric forms, respectively, by SDS-PAGE under reducing conditions.

-80

-80

Lyophilized from sterile PBS, pH 7.4

365

≥90% as determined by SDS-PAGE